# Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

Source: https://onco.cc/trials/nct05853575/  
OnCo record `nct05853575` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Adagrasib in metastatic cancer, run by Mirati Therapeutics Inc., active and no longer recruiting.

## Summary

Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) is a phase 2 interventional study registered as NCT05853575 by Mirati Therapeutics Inc., with 200 participants planned, started 2024-02-01 and due to reach its primary completion in 2026-10-30. Interventions recorded: Adagrasib. Conditions listed: Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05853575
- Phase: 2
- Setting: A Randomized Study of Two Dosing Regimens of Adagrasib in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation
- Sponsor: Mirati Therapeutics Inc.
- Enrolled: 200

## Sources

- ClinicalTrials.gov NCT05853575: https://clinicaltrials.gov/study/NCT05853575

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Adagrasib](https://onco.cc/drugs/adagrasib/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct05853575.json